A clinical isolated avirulent strain protects against wildtype virulent clostridioides difficile infection
AssigneeThe University of Chicago
InventorsEric PAMER, Qiwen DONG
Life of this patent
Estimating the term…
Abstract
Aspects herein concern cdtR mutations that can lead to reduced or absent virulence in C. difficile bacteria. Disclosed are compositions and methods using the cdtR mutants to treat or prevent C. difficile infections or diseases caused by C. difficile. Also disclosed are methods for detecting or determining C. difficile virulence based on mutation status of the cdtR gene in C. difficile.
Claims72
A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell having a reduced cdtR protein expression relative to a wild type C. difficile.
A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell that expresses a mutant cdtR protein.
A method for treating and/or preventing C. difficile pathogenesis, the method comprising administering to a patient a C. difficile cell that does not express a functional cdtR protein.
A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile ST1-75 (ATCC Deposit Number PTA-127589).
A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile ST1-35 (ATCC Deposit Number PTA-127588).
A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile ST1-75 (ATCC Deposit Number PTA-127589).
A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile ST1-35 (ATCC Deposit Number PTA-127588).
A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile cdtRmut6.1.
A method for preventing C. difficile pathogenesis, the method comprising administering to a patient C. difficile cdtRmut8.1.
A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile cdtRmut6.1.
A method for treating pathogenic C. difficile infection, the method comprising administering to a patient C. difficile cdtRmut8.1.
A Clostridioides difficile (C. difficile) cell that expresses a mutant cdtR protein.
A C. difficile cell having a reduced cdtR protein expression relative to a wild type C. difficile.
A C. difficile cell that does not express a functional cdtR protein.
A composition comprising two or more of C. difficile ST1-75 (ATCC Deposit Number PTA-127589), C. difficile ST1-35 (ATCC Deposit Number PTA-127588), C. difficile cdtRmut6.1, and C. difficile cdtRmut8.1.
A method for analyzing virulence of a bacteria strain present in an infection in a patient, the method comprising identifying a cdtR gene in the bacteria strain.
A method of treating a bacterial infection in a patient, the method comprising administering a therapeutic intervention to the patient, wherein a cdtR gene has been identified in the bacterial infection.
A method of reducing virulence of a bacterium, the method introducing a cdtR mutant gene to the bacterium.
A bacteriophage comprising an engineered genome encoding a cdtR mutant gene.
Dependencies are inferred from the claim text.